mild cognitive impairment
Conditions
Interventions
Exposure Group:Patients for whom Yizhi Qingzhuo Yin (composed of: Polygonati Rhizoma [Huangjing] 5g, Mori Fructus [Sangshen] 5g, Lycii Fructus [Gouqi] 5g, Citri Reticulatae Pericarpium [Chenpi] 3g, Pu
Non-Exposure Group:Patients who did not receive Yizhi Qingzhuo Yin during the same period. Their chronic disease management plans-which could include other Chinese herbal medicines, Western pharmaceut
other Chinese herbal infusions for daily drinking (e.g., Jianpi Zishen Fang [Spleen-Fortifying Kidney-Nourishing Formula])
non-pharmacological interventions (e.g., dietary counseling, exercise guidance).
Sponsors
Medicine affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Age = 50 years, regardless of gender; (2) Concurrent diagnosis of = 2 of the following chronic conditions: Hypertension, Diabetes mellitus, Hyperlipidemia, Coronary heart disease, Obesity (BMI = 28 kg/m²), Hyperuricemia, History of cerebral infarction or intracerebral hemorrhage (current modified Rankin Scale [mRS] score = 2), Non-advanced malignancy (non-stage IV, clinically stable, not requiring active chemotherapy/radiotherapy); (3) Meet the core clinical criteria for Mild Cognitive Impairment (MCI) as defined in the 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Disorders (V): Diagnosis and Treatment of Mild Cognitive Impairment; (4) Self-reported and/or informant-reported cognitive decline within the past 6-12 months, with preserved or largely preserved independence in basic activities of daily living (e.g., assessed by the Activities of Daily Living [ADL] scale); (5) Neuropsychological assessment confirming: Montreal Cognitive Assessment (MoCA) score = 26; (6) Education level = 6 years; (7) Able to communicate effectively in Mandarin Chinese; (8) Willing to participate in the study, provide written informed consent, and able to comply with scheduled follow-up assessments.
Exclusion criteria
Exclusion criteria: (1) Cognitive impairment attributed to a clearly identified cause other than MCI (e.g., dementia, Parkinson's disease dementia, brain tumor, sequelae of encephalitis, etc.); (2) Severe systemic illness: End-stage organ failure; Active malignancy; (3) Acute exacerbation of psychiatric disorders (e.g., major depressive episode, unremitted schizophrenia); (4) Severe sensory/motor impairment precluding participation in assessments (e.g., blindness, deafness, aphasia, hemiplegia); (5) Chronic use of medications known to impair cognition (e.g., benzodiazepines, potent anticholinergics) that cannot be adjusted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total and domain-specific scores of the Montreal Cognitive Assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mini-Mental State Examination Total Score;Short Form 36 Health Survey Summary Scores;Physical/Mental Domain Score;Blood Pressure Value;Glycated Hemoglobin, HbA1c;Low-Density Lipoprotein Cholesterol, LDL-C;Body Mass Index, BMI;Serum Uric Acid, SUA; | — |
Countries
China
Contacts
Public ContactYizhan Wang
Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Outcome results
None listed